Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05778331
Other study ID # MS 862/2022/2023
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date January 10, 2023
Est. completion date September 2023

Study information

Verified date March 2023
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

prospective observational study over POSEIDON group 3 and POSEIDON group 4 with antagonist protocol for clinical pregnancy rate outcomes


Description:

Type of study: prospective observational study. Study setting: Ain Shams University Maternity Hospital (IVF. unit) Specialized IVF centers in GIZAH Study period: Until all needed patients have been recruited (about 6 months from start of the study). Study population: women who attend IVF clinic who will be categorized as poor ovarian responders specifically those categorized as Poseidon group 3 and Poseidon group 4 are planning to undergo ICSI/IVF. Sampling method: patients will be divided in 2 groups : Group A Poseidon group 3 & Group B Poseidon group 4. Sample size: The study will be conducted on 340 patients. Sample justification: Using PASS 15 program for sample size calculation , setting power at 80% and α-error at 0.05 , and assuming clinical pregnancy rate of 21.3% for Poseidon group 3 and 10.3% for Poseidon group 4 , sample size of 170 women per group will be needed to detect difference between groups (RK abdullah , 2020). Ethical consideration: The study will be done after the approval of the ethical committee of the department of obstetrics and gynecology, faculty of medicine, Ain Shams University. Informed consent will be taken from all participants before recruitment in the study, and after explaining the purpose and procedures of the study. The investigator will obtain the written, signed informed consent of each subject prior to performing Specific procedures on the subject. The investigator will retain the original signed informed consent form. The study will be based on the investigator self-funding. Study procedure: 1. Full history will be taken from targeted women (personal, previous obstetric, menstrual, surgical, previous ICSI). 2. Labs will be revised especially AMH , FSH , LH , E2 , prolactin , TSH. 3. AFC on day 2 or 3 of menses. 4. Full labs for chronic disease will be revised to exclude women with any chronic disease. 5. Ultrasound at least to exclude any anatomical uterine problem. 6. HSG . 7. Women who will be categorized as Poseidon group 3 (Group A) and Poseidon group 4 (Group B). 8. They will be given after that antagonist protocol with dose of HMG/FSH 300-450 I.U. per day: (Gonapure 150 I.U -follicle stimulating hormone FSH preparation of recombinant DNA technology- MinaPharm pharmaceuticals-Egypt) will be given from 2nd day of menstruation per day as starting dose then on 7th day (Cetrotide 0.25 -Cetrorelix, an anti-gonadotropin releasing hormone- MERCK SORONO-Germany) will be given daily till triggering . US will be done to evaluate follicular size from 7th day if it will be 1.8 cm or more for at least 2 follicles then (Chorimon 5000 i.u-Choriogonadotropin Alfa-IBSA-Switzerland )of total dose 10000 I.U. will be given then ovum pick up with be done after 35 h of triggering ovulation (B.C. Tarlatzis, 2006). 9. Assessment of embryo quality by embryologist on day 2 and day 3 to grade embryos and also checking of blastocyst formation on day 5. 10. Embryo transfer (ET) will be done when it is on day 3 or day 5 based on the number and quality of available embryos.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 340
Est. completion date September 2023
Est. primary completion date July 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 25 Years to 50 Years
Eligibility Inclusion Criteria: (Poseidon group 4) 1. Age : = 35 years old 2. AFC : < 5 3. AMH : < 1.2 4. Planning for IVF (Poseidon group 3) 1. Age : < 35 2. AFC: < 5 3. AMH : < 1.2 4. Planning for IVF Exclusion Criteria: 1. Chronic medical disorders such as : hypertension, diabetes, etc as it may affect embryo quality and pregnancy rate . 2. Evidence of intrauterine pathology ( polyp , fibroid , adenomyosis) as it affect implantation rate. 3. Evidence uterine congenital anomaly(septum , bicornuate ) as it affects implantation rate. 4. Evidence of hydrosalpinx as it affects implantation rate. 5. Infertility due to azoospermia (male case of infertility) as it affects the rate of fertilization. 6. Patients already on other therapies(DHEA ,steroids, etc) as it affects pregnancy rate.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Antagonist protocol for induction of ovulation
Full labs will be revised to exclude women with any chronic disease. Ultrasound to exclude any anatomical uterine problem.HSG.Women who will be categorized as Poseidon group 3 and Poseidon group 4.They will be given after that antagonist protocol with dose of HMG/FSH 300-450 I.U. per day: (Gonapure 150 I.U -follicle stimulating hormone FSH preparation of recombinant DNA technology- MinaPharm pharmaceuticals-Egypt) will be given from 2nd day of menstruation per day as starting dose then on 7th day (Cetrotide 0.25 -Cetrorelix, an anti-gonadotropin releasing hormone- MERCK SORONO-Germany) will be given daily till triggering . US will be done to evaluate follicular size from 7th day if it will be 1.8 cm or more for at least 2 follicles then (Chorimon 5000 i.u-Choriogonadotropin Alfa-IBSA-Switzerland )of total dose 10000 I.U. will be given then ovum pick up with be done after 35 h of triggering ovulation .Assessment of embryo quality

Locations

Country Name City State
Egypt Ain Shams University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical pregnancy rates. number of clinical pregnancy/ number of embryo transfer cycle for each group Untill all patient has been recruited - about 6 months
Secondary Implantation rate after embryo transfer number of gestational sac/ total number of transferred embryo Untill all patient has been recruited - about 6 months
Secondary Number of high quality grade A embryos on day 3 and blastocyst. number of grade A embryos Untill all patient has been recruited - about 6 months
Secondary Fertilization rate. number of fertilized ovum / number of retrieved oocyte Untill all patient has been recruited - about 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting NCT05358483 - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Completed NCT03177538 - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Phase 4
Completed NCT03638856 - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy N/A
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn NCT04753736 - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC N/A
Completed NCT03349905 - Deferred Versus Fresh Embryo Transfers N/A
Completed NCT05076981 - Progesterone Levels During Ovulation and Luteal Phase
Completed NCT04096027 - Cabergoline Before or After Oocyte Collection for Follicular Resolution Phase 4
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Terminated NCT01933633 - Improved Fertility After Exercise in Overweight/Obese Women N/A
Terminated NCT01202643 - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF Phase 1/Phase 2
Completed NCT01202656 - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Phase 1/Phase 2
Completed NCT01408615 - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation NCT05698550 - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET Phase 3
Not yet recruiting NCT03910582 - Personalized FET in RIF Patients With Displaced Dating N/A
Completed NCT05440019 - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed NCT05130125 - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer